Emerade adrenaline auto-injectors supply update
UPDATE: For guidance on how to use your Emerade auto-injector and tell if your pen has fired view informative videos here
Bausch + Lomb is committed to helping ensure that patients have access to the medicines they need, and they are working diligently to help supply the market with this critical medicine. Over the last year they have seen a large increase in demand for their products due to supply issues with EpiPen and have worked very closely with their manufacturing partners to substantially increase production across our range of Emerade 150mcg, 300mcg and 500mcg Adrenaline Auto-Injectors(AAIs) to help support patients.
Please note a Caution in Use Notification was issued by the MHRA on the 11th of July regarding Emerade. All stock manufactured after the 30th of June 2019 will have the corrective actions referred to in the notification implemented.
Emerade 500mcg (Adrenaline Tartrate)
We are currently experiencing some delays in the next supply of Emerade 500mcg (Adrenaline tartrate) which will not be available until the 28th of August in UK wholesalers. This is caused by manufacturing issues experienced by our Swedish manufacturing partner, relating to its production line, which has led to a temporary decrease in output.
Emerade 300mcg (Adrenaline Tartrate)
A limited supply of Emerade 300mcg (Adrenaline Tartrate) has been distributed to wholesalers and we are working with our supply chain to ensure that this is optimized to be available to patients with a valid Emerade 300mcg prescription. The next shipment will be available in September.
Emerade 150mcg (Adrenaline Tartrate)
There is good supply of Emerade 150mcg (primarily a paediatric dose) which should be available in pharmacy and wholesale.
Bausch + Lomb advise that patients should seek advice from your Health Care Practitioner on suitable alternatives should your current AAI be unavailable.
How did the MHRA come up with the numbers for reduced risk by carrying two pens instead of one?
If one pen is carried, the risk of not having a pen that is working and therefore being unable to administer adrenaline is 0.23% (2.3 in 1,000 or a probability 0.0023). The risk of one pen being faulty is independent of the risk that another pen is faulty as the potential defect is not linked to a particular batch. Therefore, to calculate the risk of not having a pen that is working if two pens are carried, i.e. both pens are faulty, one needs to multiply together the probabilities of each pen being faulty. When these probabilities are multiplied (0.0023 x 0.0023) the result is 0.00000529 which when converted back to a percentage is 0.000529%, a chance of 5.29 per million. Therefore the risk is substantially reduced by carrying two pens.